SentiAR Announces FDA 510K Clearance of Heart Surgery Augmented Reality Tech
EQ IQ- 2 Min Read
676 Views- Visitors
In order to offer transparency into how our stories are produced and to teach our readers about the importance of media literacy online, EQ's editorial team provides a quick self-rating of the integrity of the articles and the facts presented against the following EQ IQ metrics.
- Published on September 30, 2020
- Last Updated October 4, 2021
- In News
- Edited by EQ
- Submitted by BioSTL Press Release
Groundbreaking mixed reality system offers handsfree interface that allows electrophysiologists to visualize cardiac anatomy in true 3D in real-time.
SentiAR, a pioneer in visualization technologies for surgical applications has announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its groundbreaking CommandEP system, the first holographic guidance system to be used during an invasive cardiac procedure. The CommandEP system allows electrophysiologists to visualize 3D electroanatomic models in real-time, via a wearable headset and offer a truly handsfree control interface providing superior visualization, which allows them to navigate accurately within the heart during a cardiac ablation procedure.
“We are giving physicians superhuman capabilities to integrate their digital environments so they can focus on patients and their treatment,” said Berk Tas, CEO of SentiAR. “SentiAR’s holographic ablation guidance system is our first of many products to come that will revolutionize interventional procedures.”
The CommandEP system receives imaging data from the electroanatomic mapping systems and creates a 3D holographic image via SentiAR’s proprietary data flow and visualization algorithms. This patented system presents a 3D image of the patient’s heart showing the real-time position of the catheters within to the physicians via a wearable headset, currently Microsoft HoloLens.
In addition to the proprietary algorithms, SentiAR deploys its unique, trade-secret AR engine to deliver uncompromising performance. The system’s unique capabilities provide physicians the tools they need in a handsfree fashion and open architecture allows easy integration into any interventional procedure facility worldwide.
The CommandEP system is now available for sale in the United States with distribution expected to begin in 2021.
“CommandEP represents a huge leap forward in cardiac ablation technology,” said Paul Buckman, member of the board of directors of SentiAR. “Our clinical and strategic partners are thrilled with the patient data showing improved navigation, and together we look forward to putting CommandEP into the hands of electrophysiologists worldwide.”
Superhero Tested in St. Louis
SentiAR successfully completed a clinical study with the CommandEP system at St. Louis Children’s and Barnes Jewish Hospitals. In addition to utilizing the CommandEP system during the procedure, physicians were asked to perform a navigation study by targeting specific points within the patient anatomy. Each navigation exercise was completed with the CommandEP system and repeated again with standard visualization tools.
The order of CommandEP and standard visualization tools utilization was randomized to avoid creating a bias. A total of 150 navigation points were collected in 16 patients who were undergoing cardiac ablation surgery.
The results of the comparative analysis showed a 44% reduction in mean navigation error with the utilization of CommandEP system over the standard visualization tools. The results of this study were published in Journal of American College of Cardiology: Clinical Electrophysiology.
“The addition of SentiAR’s holographic guidance system provides electrophysiologists with a game-changing platform for mapping and interventional procedures,” said John K. Triedman, M.D., Chief of Cardiac Electrophysiology at Boston Children’s Hospital. “The ability to see the models in 3D in real-time, to look inside chambers and around corners while moving and rotating the model allows us to gain a better and more precise understanding of cardiac anatomy.”
“We anticipate being able to easily integrate the CommandEP system with our existing EP lab workflows. The powerful tools CommandEP provides have real potential to allow electrophysiologists to perform more accurate procedures.”
BioGenerator and Cultivation Capital Life Sciences Fund are the lead investors in SentiAR. Charlie Bolten, Senior Vice President of BioGenerator, and William Schmidt, Managing Director of Cultivation Capital’s Life Sciences Fund, are members of SentiAR’s board of directors.